Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05780905 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 5, 2024 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Apr 3, 2023 to Jan 11, 2024 · Site details revised · Study description expanded, about 4 wordsv2 Show 3 more changesShow less
    • Start date changed from estimate of Apr 3, 2023 to Jan 11, 2024
    • Site details revised
    • Study description expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University of Washington
354 trials monitored
See 17 trials at risk
Diabetes
4,286 trials monitored
See 187 trials at risk
Stroke
3,289 trials monitored
See 141 trials at risk
Type 2 Diabetes
2,100 trials monitored
See 102 trials at risk
A human subjects research study, the primary purpose of which is to assess the EFFECTS OF SEMAGLUTIDE ON INTRACRANIAL BLOOD FLOW AND BLOOD-BRAIN BARRIER PERMEABILITY IN TYPE-2 DIABETES (T2D) through testing of the intervention on patients in a clinical setting. The study will randomize subjects with diabetes to either semaglutide or matching placebo. Magnetic resonance images will be primary endpoint measured at baseline and at one year to assess effect of this FDA approved medication. Given the available evidence supporting the neuroprotective effect of this drug class and stroke reduction with semaglutide, and the investigators preliminary data showing that T2D had significantly reduced total number of distal arterial branches in the brain than non-T2D, the investigators expect treatment with semaglutide will be associated with improved intracranial blood flow condition.
Trial Details
NCT Number NCT05780905
Lead Sponsor University of Washington
Collaborators: Novo Nordisk A/S
Conditions Diabetes Mellitus, Type 2, Stroke (CVA) or Transient Ischemic Attack
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov